Cardiol Rev. 2025 Oct 31. doi: 10.1097/CRD.0000000000001114. Online ahead of print.
ABSTRACT
Large-scale clinical trials of intensive glycemic control have failed to show cardiovascular benefit, with hypoglycemia implicated as a key factor. Increasing evidence suggests hypoglycemia is not merely a complication of diabetes therapy but an independent risk factor for cardiovascular disease. Acutely, hypoglycemia triggers sympathoadrenal activation leading to tachycardia, increased contractility, and blood pressure changes, alongside electrophysiological disturbances such as QTc prolongation and arrhythmias. It also induces platelet activation, endothelial dysfunction, and a prothrombotic state, creating a myocardial oxygen demand-supply mismatch that predisposes to acute coronary events. Chronically, recurrent hypoglycemia contributes to cumulative cardiac injury, structural remodeling with fibrosis, impaired contractile reserve, heart failure development, and potential electrophysiological adaptation that heightens arrhythmic vulnerability. Together, these acute and chronic effects highlight that like hyperglycemia, hypoglycemia also confers significant cardiovascular risk. Glucose-lowering strategies, especially in diabetic individuals already at higher cardiovascular risk, should therefore be individualized with careful avoidance of both extremes to optimize outcomes and minimize harm.
PMID:41632550 | DOI:10.1097/CRD.0000000000001114